Navigation Links
Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
Date:12/8/2011

HORSHAM, Pa., Dec. 8, 2011 /PRNewswire-FirstCall/ -- Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ), announced today that it has executed an agreement with Pharmacyclics, Inc. (Nasdaq: PCYC) to jointly develop and market the anti-cancer compound, PCI-32765.  A number of Phase 1 and 2 studies with PCI-32765 are ongoing across a panel of B-cell malignancy disorders, including chronic lymphocytic leukemia, mantle cell lymphoma, and diffuse large B-cell lymphoma.  Interim data were reported at the 2011 American Society of Clinical Oncology Annual Meeting and oral presentations on two separate Phase 2 studies will be presented at the upcoming American Society of Hematology Meeting in December, along with several other poster presentations.

"The agreement with Pharmacyclics is an opportunity to bring a new form of oral therapy to patients with B-cell malignancies," said William N. Hait, M.D., Ph.D., Global Therapeutic Head, Oncology, for Janssen.  "PCI-32765 is an innovative compound, with broad applicability and the potential to help a large number of patients with B-cell malignancies."

According to the terms of the agreement, the companies have entered into a worldwide 50/50 profit-loss agreement, sharing development and commercialization activities.  Janssen has made an upfront payment of $150 million which will be recorded in the fourth quarter, and will make additional payments based upon the achievement of certain development and regulatory milestones.  This transaction is expected to have a dilutive impact to Johnson & Johnson's 2011 earnings per share of approximately $0.04 - $0.05.

About PCI-32765

PCI-32765 is an orally active, small molecule inhibitor of Bruton's tyrosine k
'/>"/>

SOURCE Janssen Pharmaceutical Companies of Johnson & Johnson
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Johnson & Johnson Symposium Honors 2011 Recipient of The Dr. Paul Janssen Award for Biomedical Research
2. FDA Issues Complete Response Letter to Janssen Biotech, Inc. for SIMPONI® Supplemental Biologic License Application
3. Skyline Diagnostics Establishes Research Collaboration With Janssen
4. Johnson & Johnson Honors 2009 Recipient of The Dr. Paul Janssen Award for Biomedical Research
5. Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research
6. Johnson & Johnson Honors 2008 Recipients of The Dr. Paul Janssen Award for Biomedical Research
7. Kibow Biotech, Inc. Secures $2.4 Million Towards Its Human Clinical Trials by Continued Veterinary Licensing Agreement
8. C3i Inc to Provide Full-Service Technology Support and Oracle Clinical, Oracle Remote Data Capture Business Process Outsourcing to XBiotech, Inc
9. Genesis Biopharma to Present at the Informed Investors Forum Biotech, Healthcare & Pharma Virtual Conference on October 13
10. For the First Time, a Glioma - Brain Cancer - may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing
11. For the First Time, a Glioma ¨C Brain Cancer ¨C may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Clinverse, Inc. , a global ... announced today it has formed a strategic alliance ... FLS eClinical commerce platform aggregates data collected through ... ™, Aggregate Spend Solutions’ recently-launched flagship product, is ... transfer of value at investigator meetings or any ...
(Date:5/21/2013)... 21, 2013 As the R&D ... push within the industry to deliver better products, ... and pharma companies often means turning big ideas ... developed in collaboration with Sensidose AB and Recipharm, ... bring products to market sooner. The partnership resulted ...
(Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. ... study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal ... expressing the HER2 oncoprotein," will be presented at ... of Clinical Oncology during the Developmental Therapeutics - ... at 4:15 – 4:30 PM.  The presentation will ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Bed bugs have ... to My Cleaning Products, many turn to chemical-based pesticides for ... the health and environmental risks those solutions present, the company ... Bed Bug Bully instead. , According to My Cleaning ... as they used to be. It shared that the pests ...
Breaking Biology Technology:Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 3
... - Probing the last genomic frontier of higher organisms, an ... understood - but critical - genetic domain in rice. , ... professor of horticulture at the University of Wisconsin-Madison , ... Research in Rockville, Md., has exposed a supposedly barren ...
... Wis. - Chippewa Valley Technical College (CVTC) ... that CVTC will begin teaching nanotechnology as early as ... sweeping changes and opportunities. , ,Jack Uldrich, nanotechnology author, ... described a shift of historic proportions brought on by ...
... , a Wisconsin-based developer of e-Catalog business solutions ... distribution networks, announced it has expanded its software ... , a manufacturer of products for the lawn ... Cub Cadet, Troy-Bilt, Yard-Man, Ryobi, Yard Machines, McCulloch ...
Cached Biology Technology:Rice Centromere, Supposedly Quiet Genetic Domain, Surprises 2Rice Centromere, Supposedly Quiet Genetic Domain, Surprises 3Chippewa Valley Embraces Nanotechnology 2ARI Links e-Catalog Deal with Outdoor Power Equipment Manufacturer 2
(Date:5/20/2013)... are also commonly resistant to antimicrobial substances made ... in mBio , the online open-access journal ... colistin and host antimicrobials LL-37 and lysozyme, which ... mean that patients with life-threatening multi-drug resistant infections ... Colistin is a last-line drug for treating several ...
(Date:5/20/2013)... ITHACA, N.Y. Little is known about the effect ... new study from Cornell University finds that increasing the ... class reduces the probability of obesity. , The study ... effect of PE on youth obesity, and is forthcoming ... An early, online version of the study can be ...
(Date:5/20/2013)... COLUMBUS, Ohio New research suggests that a compound ... "superpower" to escape death. , By altering a ... re-educates cancer cells into normal cells that die as ... by inhibiting a process that would cause them to ... strict programming. This study in cells, led by Ohio ...
Breaking Biology News(10 mins):Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3Gym class reduces probability of obesity, study finds for first time 2The compound in the Mediterranean diet that makes cancer cells 'mortal' 2The compound in the Mediterranean diet that makes cancer cells 'mortal' 3
... The Food and Drug Administration (FDA) today issued a ... and patient caregivers to new safety information concerning an ... antipsychotic drugs." These drugs are approved for the treatment ... drugs to treat behavioral disorders in elderly patients with ...
... mammalian behavior, physiology, and biochemistry are controlled by the ... suprachiasmatic nucleus (SCN). The clock is synchronized to environmental ... from everyday experience, that adjusting to new light schedules ... adaptation takes place are not well understood. Researchers now ...
... results from a large, randomized clinical trial for ... cancer ?cancer that has spread from the breast ... those patients who received bevacizumab (Avastin? in combination ... before their cancer progressed than patients who received ...
Cached Biology News:FDA Warns About Antipsychotic Drugs and Elderly 2After a time-shift, mixed signals from the circadian clock 2Bevacizumab Combined With Chemotherapy Improves Progression-Free Survival for Patients With Advanced Breast Cancer 2Bevacizumab Combined With Chemotherapy Improves Progression-Free Survival for Patients With Advanced Breast Cancer 3
IMAGEQUANT 300 WKSTN, 1 EA. Category: ImageQuant CCD Imagers....
ANTI MYCOBACTERIUM TUBERCULOSIS...
IMAGEQUANT 100 WKSTN, 1 EA. Category: ImageQuant CCD Imagers....
IMAGEQUANT 300 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
Biology Products: